{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-103772","form_type":"8-K","ticker":"PFSA","cik":"0001859807","company_name":"Profusa, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.851751+00:00","generated_at":"2026-05-17T01:25:00.223123+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"confidence":"high","headline":"Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026","bullets":["EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.","2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.","US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.","Estimates 35% European population coverage through intended distribution channels.","Targets $10.5B tissue oxygen market and >500M glucose monitoring population."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-103772","json":"https://secwatch.observer/filing/0001213900-25-103772.json","markdown":"https://secwatch.observer/filing/0001213900-25-103772.md","text":"https://secwatch.observer/filing/0001213900-25-103772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/0001213900-25-103772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/ea0263091-8k_profusa.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:25:00.223123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}